SG11201807652SA - Derivatives of amanita toxins and their conjugation to a cell binding molecule - Google Patents
Derivatives of amanita toxins and their conjugation to a cell binding moleculeInfo
- Publication number
- SG11201807652SA SG11201807652SA SG11201807652SA SG11201807652SA SG11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA SG 11201807652S A SG11201807652S A SG 11201807652SA
- Authority
- SG
- Singapore
- Prior art keywords
- hangzhou
- heda
- zhejiang
- street
- room
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2016/052246 WO2017046658A1 (en) | 2016-04-20 | 2016-04-20 | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807652SA true SG11201807652SA (en) | 2018-10-30 |
Family
ID=58288166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807652SA SG11201807652SA (en) | 2016-04-20 | 2016-04-20 | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
Country Status (15)
Country | Link |
---|---|
US (1) | US10836796B2 (es) |
EP (1) | EP3445401A4 (es) |
JP (2) | JP7295640B2 (es) |
KR (1) | KR102295190B1 (es) |
CN (2) | CN109689107B (es) |
AU (1) | AU2016322708B2 (es) |
BR (1) | BR112018071465A2 (es) |
CA (1) | CA3016172C (es) |
MX (1) | MX2018012803A (es) |
MY (1) | MY197235A (es) |
NZ (1) | NZ744936A (es) |
PH (1) | PH12018501777A1 (es) |
SG (1) | SG11201807652SA (es) |
WO (1) | WO2017046658A1 (es) |
ZA (1) | ZA201807613B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016059622A2 (en) | 2016-02-04 | 2016-04-21 | Suzhou M-Conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
MY197235A (en) * | 2016-04-20 | 2023-06-07 | Hangzhou Dac Biotech Co Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
US20190328901A1 (en) | 2016-06-17 | 2019-10-31 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
US20210308277A1 (en) * | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
BR112019020049A2 (pt) * | 2017-04-06 | 2020-05-12 | Hangzhou Dac Biotech Co., Ltd | Composto conjungado, célula tumoral, composição farmacêutica, e, agentes sinérgicos. |
JP7220199B2 (ja) * | 2017-08-07 | 2023-02-09 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマニチンの新規な合成方法 |
CN114191564A (zh) * | 2017-08-18 | 2022-03-18 | 四川百利药业有限责任公司 | 一种非天然鹅膏毒肽类抗体偶联物 |
KR20190043031A (ko) * | 2017-10-17 | 2019-04-25 | 한국화학연구원 | 아마톡신 유도체 및 이의 제조방법 |
EP3700540A4 (en) * | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS |
MX2020004140A (es) | 2017-10-24 | 2020-08-13 | Magenta Therapeutics Inc | Composiciones y metodos para la eliminacion de celulas cd117+. |
KR102641565B1 (ko) * | 2017-12-31 | 2024-02-27 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 분지형 링커를 갖는 튜불리신 유사체의 접합체 |
CN109096128B (zh) * | 2018-01-12 | 2021-03-09 | 江苏金斯瑞生物科技有限公司 | 一种氨基聚乙二醇丙酸的制备方法 |
KR20210083282A (ko) * | 2018-12-17 | 2021-07-06 | 레메젠 코, 리미티드 | 항체-약물 컨쥬게이트에 사용하기 위한 커넥터 및 커넥터의 적용 |
JP2022523103A (ja) * | 2019-01-31 | 2022-04-21 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 分岐連結体とアマニタトキシンとの共役体 |
EP3958908A1 (en) | 2019-04-24 | 2022-03-02 | Heidelberg Pharma Research GmbH | Amatoxin antibody-drug conjugates and uses thereof |
CN114040779A (zh) * | 2019-06-24 | 2022-02-11 | 杭州多禧生物科技有限公司 | 含支链连接子的细胞结合分子与细胞毒性剂的偶联物 |
KR102092817B1 (ko) * | 2019-08-22 | 2020-03-24 | 한국화학연구원 | 아마톡신 유도체 및 이의 제조방법 |
TWI710488B (zh) | 2019-09-18 | 2020-11-21 | 亞慶股份有限公司 | 高爾夫球車煞車系統的自駕煞車暨手駕煞車連接組件 |
AR120218A1 (es) * | 2019-10-15 | 2022-02-02 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo específico de linfocitos b |
US20230039142A1 (en) * | 2019-12-16 | 2023-02-09 | Heidelberg Pharma Research Gmbh | Synthesis of amanin and its derivatives |
CN111233949A (zh) * | 2020-02-10 | 2020-06-05 | 天津科技大学 | 一种神经节苷脂gm3和/或其类似物、合成方法和应用 |
WO2021255217A1 (en) * | 2020-06-19 | 2021-12-23 | Heidelberg Pharma Research Gmbh | Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication |
WO2024154763A1 (ja) * | 2023-01-17 | 2024-07-25 | 大塚製薬株式会社 | 抗体薬物複合体用リンカーおよび抗体薬物複合体 |
CN116284224B (zh) * | 2023-05-12 | 2023-07-25 | 中国农业大学 | 一种结合Claudin 18.2的环肽及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001270863A (ja) * | 2000-03-23 | 2001-10-02 | Mitsui Chemicals Inc | 6−置換インドール誘導体の製造方法 |
CA2970774C (en) | 2009-04-08 | 2019-01-08 | Deutsches Krebsforschungszentrum | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
DK2675479T3 (en) * | 2011-02-15 | 2016-04-11 | Immunogen Inc | cytotoxic benzodiazepine |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
US20150218220A1 (en) | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
WO2015028850A1 (en) * | 2013-09-02 | 2015-03-05 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
AU2015242213A1 (en) * | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
CA2991975C (en) * | 2015-08-10 | 2021-04-06 | Suzhou M-Conj Biotech Co., Ltd. | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
WO2016059622A2 (en) | 2016-02-04 | 2016-04-21 | Suzhou M-Conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
MY197235A (en) * | 2016-04-20 | 2023-06-07 | Hangzhou Dac Biotech Co Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
-
2016
- 2016-04-20 MY MYPI2018703127A patent/MY197235A/en unknown
- 2016-04-20 KR KR1020187028837A patent/KR102295190B1/ko active IP Right Grant
- 2016-04-20 CN CN201680084667.1A patent/CN109689107B/zh active Active
- 2016-04-20 BR BR112018071465A patent/BR112018071465A2/pt not_active Application Discontinuation
- 2016-04-20 CA CA3016172A patent/CA3016172C/en active Active
- 2016-04-20 WO PCT/IB2016/052246 patent/WO2017046658A1/en active Application Filing
- 2016-04-20 SG SG11201807652SA patent/SG11201807652SA/en unknown
- 2016-04-20 MX MX2018012803A patent/MX2018012803A/es unknown
- 2016-04-20 CN CN202210785106.1A patent/CN115181164A/zh active Pending
- 2016-04-20 AU AU2016322708A patent/AU2016322708B2/en active Active
- 2016-04-20 EP EP16845791.9A patent/EP3445401A4/en active Pending
- 2016-04-20 NZ NZ744936A patent/NZ744936A/en unknown
- 2016-04-20 JP JP2018554563A patent/JP7295640B2/ja active Active
- 2016-04-20 US US16/078,080 patent/US10836796B2/en active Active
-
2018
- 2018-08-20 PH PH12018501777A patent/PH12018501777A1/en unknown
- 2018-11-13 ZA ZA2018/07613A patent/ZA201807613B/en unknown
-
2022
- 2022-12-16 JP JP2022201500A patent/JP2023051977A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112018071465A2 (pt) | 2019-02-05 |
CN109689107B (zh) | 2022-08-16 |
EP3445401A4 (en) | 2019-11-20 |
CA3016172C (en) | 2024-03-12 |
KR20180125154A (ko) | 2018-11-22 |
CN109689107A (zh) | 2019-04-26 |
US10836796B2 (en) | 2020-11-17 |
CN115181164A (zh) | 2022-10-14 |
JP2019515907A (ja) | 2019-06-13 |
MY197235A (en) | 2023-06-07 |
US20200079820A1 (en) | 2020-03-12 |
KR102295190B1 (ko) | 2021-08-30 |
JP7295640B2 (ja) | 2023-06-21 |
WO2017046658A1 (en) | 2017-03-23 |
MX2018012803A (es) | 2019-06-24 |
NZ744936A (en) | 2022-01-28 |
AU2016322708A1 (en) | 2018-08-23 |
AU2016322708B2 (en) | 2020-08-20 |
PH12018501777A1 (en) | 2019-05-15 |
CA3016172A1 (en) | 2017-03-23 |
EP3445401A1 (en) | 2019-02-27 |
JP2023051977A (ja) | 2023-04-11 |
ZA201807613B (en) | 2022-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807652SA (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
SG11201908721TA (en) | Conjugation of a cytotoxic drug with bis-linkage | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
SG11201901374WA (en) | Antibiotic compounds | |
SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201906417RA (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
SG11201908226XA (en) | Rapamycin analog |